Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10601664 | 0.83 | MAPT (0.54) | MAPTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL15453215 | 0.82 | ALDH1A1 (0.52) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL12294284 | 0.81 | LMNA (0.47) | MAPTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL6251433 | 0.81 | RAB9A (0.53) | MAPTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL1086165 | 0.80 | ALDH1A1 (0.56) | RAB9ASMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL13026260 | 0.79 | HDAC2 (0.55) | MAPTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL2345447 | 0.79 | ALDH1A1 (0.60) | MAPTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL7885609 | 0.78 | ALDH1A1 (0.48) | MAPTSMN1; SMN2KDM4EKMT2AALDH1A1 | |
| SCHEMBL1086084 | 0.78 | ALDH1A1 (0.54) | RAB9ASMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL1176396 | 0.78 | SMN1; SMN2 (0.61) | MAPTRAB9ANPC1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| WO-2023125530-A1 | ANTIBODY DRUG CONJUGATES | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| EP-4198060-A1 | POLYSACCHARIDE DERIVATIVE, POLYSACCHARIDE DERIVATIVE-DRUG CONJUGATE, AND METHOD FOR PRODUCING SAME | The University of Tokyo (JP) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-3157515-B1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | PLACON THERAPEUTICS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3797768-A1 | MALEIMIDE-FUNCTIONALISED PLATINUM FOR USE IN THE TREATMENT OF CANCER | Placon Therapeutics, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20170340749-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9669102-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160367698-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2016-12-22 | — | — | US | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
| US-20030073733-A1 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002083083-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | KING PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | disclosed |
| EP-0512352-B1 | Substituted carboxylic acid derivatives | HOFFMANN LA ROCHE (CH) | 1996-03-27 | — | — | EP | disclosed |
| US-5344843-A | Carnitine acryltransferase enzyme inhibitors as antiischemic agents and for cardiovascular disorders | HOFFMAN-LA ROCHE INC. (US) | 1994-09-06 | — | — | US | disclosed |
| EP-0512352-A2 | Substituted carboxylic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367698-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | MAPT 4072/4885RAB9A 2398/4885NPC1 515/4885 |
| US-20030073733-A1 | Pharmaceutically active compounds and methods of use | TRPV1, TPMT, ACHE | MAPT 1176/4885RAB9A 1503/4885NPC1 931/4885 |
| US-20170340749-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | MAPT 4072/4885RAB9A 2398/4885NPC1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.